Jazz Pharmaceuticals (NASDAQ:JAZZ) Issues Quarterly Earnings Results

Jazz Pharmaceuticals (NASDAQ:JAZZ) announced its earnings results on Monday. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.18 by ($0.47), FiscalAI reports. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The company’s revenue for the quarter was up 15.5% compared to the same quarter last year. During the same period last year, the firm earned ($8.25) EPS.

Here are the key takeaways from Jazz Pharmaceuticals’ conference call:

• Record revenue of $1.21 billion rose 16% year over year, prompting Jazz to raise 2026 revenue guidance to $4.60 billion–$4.75 billion. Adjusted EPS was $5.71, while first-half operating cash flow reached $824 million.
• XYWAV sales increased 13% to $471 million, with approximately 525 net patient additions and limited uptake of high-sodium generics. Jazz now expects double-digit XYWAV growth in 2026 and raised rare-sleep revenue guidance to $2.025 billion–$2.125 billion.
• Epidiolex sales grew 16% to $292 million on strong underlying demand, particularly among adult and long-term-care patients. Jazz is pursuing a capsule formulation and several clinical trials to expand usage across additional treatment-resistant seizure populations.
• Jazz expressed high confidence in zanidatamab’s approval for first-line HER2-positive metastatic GEA by the August 25 PDUFA date and said it is prepared for launch. The company highlighted median overall survival of 26.4 months in the combination arm and expects additional doublet overall-survival data in the third quarter.
• Zepzelca sales rose 42% to $106 million, driven by first-line maintenance adoption, but Jazz plans to submit a labeling supplement removing the second-line indication after the LAGOON results. Management expects the historical second-line business to continue eroding, with a possible acceleration following the label change.

Jazz Pharmaceuticals Trading Down 0.5%

JAZZ opened at $251.58 on Tuesday. The stock has a market capitalization of $15.80 billion, a PE ratio of -12,572.71, a P/E/G ratio of 0.22 and a beta of 0.32. Jazz Pharmaceuticals has a one year low of $105.00 and a one year high of $261.30. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. The business’s 50 day moving average price is $239.50 and its 200 day moving average price is $207.30.

Insider Buying and Selling

In other news, Director Heather Ann Mcsharry sold 2,000 shares of the firm’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $241.00, for a total transaction of $482,000.00. Following the completion of the transaction, the director directly owned 18,449 shares in the company, valued at $4,446,209. This trade represents a 9.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Neena M. Patil sold 1,200 shares of the firm’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total value of $278,196.00. Following the transaction, the executive vice president owned 51,549 shares of the company’s stock, valued at $11,950,604.67. This trade represents a 2.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 13,098 shares of company stock valued at $3,131,906 over the last three months. Company insiders own 4.10% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Several hedge funds have recently made changes to their positions in JAZZ. Danske Bank A S acquired a new stake in Jazz Pharmaceuticals during the 3rd quarter worth approximately $40,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Jazz Pharmaceuticals by 1,383.3% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 332 shares in the last quarter. Geneos Wealth Management Inc. increased its stake in Jazz Pharmaceuticals by 57.6% in the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares during the last quarter. Sunbelt Securities Inc. purchased a new position in Jazz Pharmaceuticals in the third quarter valued at approximately $53,000. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth approximately $63,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

More Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz reported second-quarter revenue of approximately $1.21 billion, up 15.5% year over year and above the $1.11 billion analyst estimate. Growth was supported by Xywav revenue increasing 13% and Epidiolex revenue rising 16%. Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised its 2026 revenue outlook to $4.6 billion-$4.8 billion, above the roughly $4.5 billion consensus estimate. Jazz also said it is prepared to launch Ziihera in first-line HER2-positive gastric or gastroesophageal junction cancer immediately after potential FDA approval. Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Analysts became more bullish following the results. Needham raised its price target from $282 to $292 and maintained a “buy” rating, while Robert W. Baird increased its target from $252 to $280 and assigned an “outperform” rating. Benzinga analyst updates
• Negative Sentiment: Second-quarter adjusted earnings of $5.71 per share missed consensus estimates ranging from $6.04 to $6.18. Although results improved substantially from a loss of $8.25 per share a year earlier, the earnings shortfall may be weighing on the stock. Jazz Pharmaceuticals Q2 Earnings Lag Estimates

Wall Street Analyst Weigh In

A number of research firms recently weighed in on JAZZ. Royal Bank Of Canada boosted their price target on shares of Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. Needham & Company LLC raised their target price on shares of Jazz Pharmaceuticals from $282.00 to $292.00 and gave the stock a “buy” rating in a research note on Tuesday. Robert W. Baird boosted their target price on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a report on Tuesday. Morgan Stanley restated an “overweight” rating and issued a $245.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, May 7th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Jazz Pharmaceuticals in a report on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $262.22.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.